A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma
Status:
Active, not recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this Phase I/II study is to evaluate safety, pharmacokinetics, and preliminary
efficacy of the investigational drug PLX3397 in subjects with unresectable or metastatic
KIT-mutated melanoma.